BE A HERO: VOLUNTEER FOR CLINICAL TRIAL OF COVID-19 THERAPIES

-

Study Title: ACTIV-2 Outpatient Monoclonal Antibodies and other Therapies (ACTG A5401).

Study Description:
ACTIV-2 is a randomized, blinded, controlled adaptive platform that allows promising investigational agents to be added and removed over the course of the study, in order to efficiently test a variety of new agents against placebo within the same trial infrastructure.

ACTIV-2 will evaluate the safety and efficacy of investigational agents to treat adults who have COVID-19 illness but do not require hospitalization. The study will also enable researchers to assess the correlation between changes in viral shedding and clinical outcomes, leading to a better understanding of whether effective medications can reduce or halt the transmission of SARS-CoV-2 (the virus that causes COVID-19) to others.

Why is this study being done?
To rapidly and efficiently evaluate multiple potential therapeutics for COVID-19 in an outpatient setting.

Who can join?
  • Ambulatory Adult (18 years or older)
  • Active SARS-CoV-2 infection <7 days prior to Entry
  • At least one typical COVID-19 symptom for <10 days prior to Entry, plus one the following symptoms present within 48 hours of entry: 
    • Fever or feeling feverish, cough, shortness of breath at rest or with activity, sore throat, body or muscle pain, fatigue, headache, chills
Duration of study: 28 days of intensive follow-up, followed by limited follow-up through 24 weeks.

Study Investigators: The AIDS Clinical Trials Group (ACTG), the world’s largest and longest established HIV research network.

Participating Clinical Research Sites (CRS):
  • Harbor University of California Los Angeles Center CRS - Torrance, California
  • Massachusetts General Hospital (MGH) CRS - Boston, Massachusetts
  • Northwestern University CRS - Chicago, Illinois
  • Ohio State University CRS - Columbus, Ohio
  • Rush University CRS - Chicago, Illinois
  • The Ponce de Leon Center CRS - Atlanta, Georgia
  • University of California, Los Angeles CARE Center CRS - Los Angeles, California
  • University of California, San Diego AntiViral Research Center CRS - San Diego, California
  • University of Colorado Denver ATN CRS - Denver, Colorado
  • University of North Carolina Global HIV Prevention and Treatment CTU - Chapel Hill, North Carolina
  • University of Pittsburgh CRS - Pittsburgh, Pennsylvania
  • University of Washington AIDS Clinical Trials Unit CRS - Seattle, Washington
  • Vanderbilt Therapeutics (VT) CRS - Nashville, Tennessee
  • Washington University Therapeutics (WT) CRS - St. Louis, Missouri
  • Weill Cornell Uptown CRS - New York, New York
For more information, click here: https://www.activ-2.org/en

Comments

Post a Comment

Popular posts from this blog

FACT CHECK: DID BOLA TINUBU CALL FOR REDUCTION OF NIGERIANS’ PURCHASING POWER?

-
Image
By Akin Ojumu  With respect to Bola Tinubu’s presidential aspiration, my position is pretty clear. Those who’ve been following my various commentaries on this issue know very well that I’m not a fan of Bola Tinubu and his unscrupulous campaign to become the next president of the Federal Republic of Nigeria.  My opposition to Bola Tinubu’s candidacy is visceral and intense. The man is a clear and present danger to the well-being of Nigeria, if he ever becomes president. BAT is an advanced metastatic cancer rapidly growing and spreading in the Nigeria polity. If the country must survive, this deadly cancer must be treated as all advanced cancers are treated; radical excision combined with several courses of radiotherapy and multiple cycles of chemotherapy cocktail in addition to the clearing of all associated lymph nodes. Now, there’s one thing I detest as much as Bola Tinubu’s presidential run, and that’s fake news. I cherish the truth, it’s the compass that guides us to safe shores. Wi
Read more

BECAUSE JOB DIDN’T TITHE, HIS LIFE BECAME TIGHT

-
Image
By Akin Ojumu Being the trust-but-verify guy that I am, while fact-checking a social media post by one of my High School friends, in which Bishop David Oyedepo was quoted to have linked the adversity of Job to his tithing habit, I was shocked, but not at all surprised, to find a 2019 video that did indeed confirm what my good friend shared.  In Bishop Oyedepo's telling, the real cause of Job's afflictions was his failure to pay tithes. According to him, God removed Job's divine security and allowed Satan to buffet him with calamity because the man was a habitual tithe defaulter. Because Job didn't tithe, his life became really tight. Here is the Bishop in his own words: “You can't see anywhere where Job tithed. So, his blessing was not secured. You can't find anywhere where Job tithed. No! He was overly committed to giving liberally to the poor and God was committed to bless him. But there was no security.” Just so it's absolutely clear. Bishop Oyedepo's
Read more

YOU CAN’T LOVE NIGERIA & WANT BOLA TINUBU AS ITS PRESIDENT

-
Image
By Akin Ojumu Asiwaju Bola Ahmed Tinubu is not a stranger to Nigerians. The man with the Graves Disease eyes has been around a long time. BAT is a vector of deadly viral disease of pandemic proportions. He is a parasite that takes over everything his hand touches.  The following is just a sample of what Bola Tinubu, allegedly, did to Lagos State: Number 4, Oyinkan Abayomi (Formerly Queens) Drive, Ikoyi – Valued at N450 Million A 5-bedroom detached house on one acre of land was Lagos State Governor’s guest house since 1979 Certificate of occupancy was signed and released to Tinubu by Fashola in 2007 26 Bourdillon Road, Ikoyi – Valued at N600 Million Originally claimed to be by Oando Plc Guest House, it was later acquired by Tinubu from Oando Lagos State Government paid to rebuild and renovate, it then purchased it from Tinubu for an undisclosed sum. Subsequently, the State handed the property back to Tinubu under the Pension Bill he signed into law shortly before Tinubu left office in 2
Read more